Preclinical studies investigating resistance mechanisms to ICIs have implicated factor X in immune escape mechanisms, suggesting a potential role for factor Xa inhibitors such as fondaparinux in enhancing the anti-tumor effects of ICIs [109,110]. Here, F10 is linked to neoplasm.